Ginkgo Bioworks Holdings, Inc.
DNA
$6.84
$0.152.24%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.83% | 47.86% | 64.89% | 44.71% | 38.73% |
| Total Depreciation and Amortization | -10.51% | -9.86% | -28.26% | -26.24% | -36.15% |
| Total Amortization of Deferred Charges | 3.89% | 40.60% | -- | -- | -- |
| Total Other Non-Cash Items | -50.10% | -57.14% | -70.21% | -51.50% | -48.88% |
| Change in Net Operating Assets | 50.83% | 63.20% | -380.34% | -454.30% | -400.53% |
| Cash from Operations | 46.47% | 50.50% | 22.07% | 4.19% | -8.15% |
| Capital Expenditure | 87.74% | 59.12% | 12.29% | -126.05% | -53.28% |
| Sale of Property, Plant, and Equipment | -11.42% | -97.18% | -56.86% | -85.37% | -85.37% |
| Cash Acquisitions | -- | 100.00% | 100.00% | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,711.39% | -11,730.29% | -44,630.95% | -13,506.80% | 477.39% |
| Cash from Investing | -286.09% | -263.66% | -221.17% | -239.03% | 22.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 60.54% | 47.43% | 37.95% | 36.07% | 30.73% |
| Issuance of Common Stock | 23,077.38% | 10,427.55% | -100.00% | -90.73% | -9.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -44.71% | 71.16% | 73.68% | 85.00% | 53.49% |
| Cash from Financing | 1,122.14% | 534.96% | 51.78% | 65.30% | 45.93% |
| Foreign Exchange rate Adjustments | 171.53% | 364.15% | 157.14% | 93.05% | 52.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.48% | -16.51% | -32.31% | -43.17% | -1.01% |